GlassScriptPhysician profile
Pamela Bariola
NPI 1598800237
$3,917.60
in general payments reported to CMS, 2019-2025
32 companies · $829 in 2025
The $829 reported for 2025 was more than what 84% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $558 · 2022: $444 · 2023: $890 · 2024: $1,197 · 2025: $829.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,916.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,915.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $943.66 | 2021-2025 | Rybelsus, Ozempic, Wegovy |
| Astrazeneca Pharmaceuticals LP | $683.32 | 2021-2025 | Airsupra, Breztri, Farxiga |
| Lilly USA, LLC | $418.07 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Abbvie INC. | $303.84 | 2021-2025 | |
| Abbott Laboratories | $197.50 | 2021-2025 | Freestyle Libre 3 |
| Bayer Healthcare Pharmaceuticals INC. | $187.97 | 2022-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $132.49 | 2023-2024 | Xifaxan, Trulance |
| Glaxosmithkline, LLC. | $130.61 | 2021-2024 | Trelegy Ellipta, Arexvy, Shingrix |
| Sanofi-Aventis U.S. LLC | $100.88 | 2023-2025 | |
| Otsuka America Pharmaceutical, INC. | $95.53 | 2023-2025 | Rexulti |
| Amgen INC. | $79.61 | 2023-2024 | Repatha, Otezla, Prolia |
| Corcept Therapeutics | $66.60 | 2025 | Korlym |
| Vanda Pharmaceuticals INC. | $51.43 | 2023-2024 | Hetlioz, Fanapt |
| Merck Sharp & Dohme LLC | $46.89 | 2021-2023 | Verquvo, Belsomra, Steglatro |
| Janssen Pharmaceuticals, INC | $44.04 | 2021-2022 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nestle Healthcare Nutrition INC. | $38.63 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $38.47 | 2021-2024 | Trintellix |
| Boehringer Ingelheim Pharmaceuticals, INC. | $36.53 | 2025 | Jardiance |
| Pfizer INC. | $34.91 | 2024-2025 | |
| Esperion Therapeutics, INC. | $34.40 | 2024-2025 | Nexletol |
| Lundbeck LLC | $33.79 | 2025 | Rexulti |
| Horizon Therapeutics Plc | $30.05 | 2021 | |
| Recor Medical INC | $29.89 | 2025 | Paradise Ultrasound Renal Denervation System |
| Boston Scientific Corporation | $21.98 | 2024 | Watchman Flx |
| Mallinckrodt Hospital Products INC. | $21.57 | 2025 | Acthar |
| Seqirus USA INC | $21.33 | 2024 | Flucelvax, Fluad |
| Acadia Pharmaceuticals INC | $19.48 | 2025 | Nuplazid |
| Phathom Pharmaceuticals, INC. | $16.21 | 2024 | Voquezna |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $14.95 | 2024 | Caplyta |
| Dexcom, INC. | $14.95 | 2024 | Dexcom G6 Transmitter |
| Viatris Specialty LLC | $14.44 | 2025 | Yupelri |
| Kowa Pharmaceuticals America, INC. | $13.58 | 2025 | Zoryve |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Pamela Bariola listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.